热门资讯> 正文

Emergsti Pharma GAAP每股收益为-1.35美元

2024-06-21 21:17

Acasti制药(ACST) 0

Acasti Pharma press release (NASDAQ:ACST): FY GAAP EPS of -$1.35.
At March 31, 2024, the Company had cash and cash equivalents of $23.0 million, as compared to $27.9 million as of March 31, 2023. The Company believes it has sufficient cash to support operations into the second calendar quarter of 2026.

More on Acasti Pharma

Seeking Alpha’s Quant Rating on Acasti Pharma
Historical earnings data for Acasti Pharma
Financial information for Acasti Pharma

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。